Top View
- Name of Policy: Perjeta® (Pertuzumab)
- HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
- Skin Care During Treatment with Epidermal Growth Factor Receptor Inhibitors (Egfri)
- (Trastuzumab-DM1) for Treatment of HER-2 Positive Malignancies
- "Use of This Document Is Governed by the Terms of Use on the First Page of This Document." # Section Comments 2020
- (CHMP) Agenda for the Meeting on 17-20 May 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
- INN Working Document 05.179 Update December 2010
- Pertuzumab for Treatment of Malignancies
- (Oncology & Haematology) Made in Its 110Th Meeting Held On
- Update on Molecular Pathology and Role of Liquid Biopsy in Nonsmall Cell Lung Cancer
- Potential and Applications of Nanocarriers for Efficient Delivery Of
- International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
- (INN) for Biological and Biotechnological Substances
- Development Beyond Breast Cancer
- Current Status and Future Directions of Targeted Agents and Immunotherapy in Gastric Cancer
- PERJETA Dosing and Administration Guide
- Blue Cross and BCN Utilization Management Medical Drug List
- And Phesgo (Pertuzumab Trastuzumab And
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- PDF of Antibody News
- Pertuzumab: Drug Information
- Trastuzumab Deruxtecan: a Quantum Leap in HER2-Positive Breast Cancer
- PERJETA® (Pertuzumab) 420 Mg/14 Ml Single-Use Vial
- Targeted Therapies
- Pertuzumab in Metastatic Breast Cancer: Unanswered Questions
- Research and Clinical Landscape of Bispecific Antibodies for The
- Strategic Collaboration in Oncology Trastuzumab Deruxtecan (DS-8201)
- Perjeta, INN-Pertuzumab
- Supplementary File 1 (PDF, 469 Kib)
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Defining the Molecular Response to Trastuzumab, Pertuzumab and Combination Therapy in Ovarian Cancer
- Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic
- Carboplatin (Auc6)-Docetaxel- Pertuzumab- Trastuzumab (Iv/Sc)
- Trastuzumab Deruxtecan
- An Overview of the Current Status of Engineered Therapeutic Monoclonal Antibodies
- ERBB2 Dimerization Inhibitor Meets End Point in Breast Cancer Trial
- Perjeta® (Pertuzumab)
- Copyrighted Material
- SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
- Medicare Model Guidelines Draft V8.0 1 of 97
- Co-Treatment with Panitumumab and Trastuzumab Augments Response
- Pertuzumab for Metastatic HER2-Positive Gastric Cancer – First Line
- Perjeta (Pertuzumab)
- Kadcyla® (Ado-Trastuzumab Emtansine)
- Enhertu (Trastuzumab Deruxtecan)
- Perjeta (Pertuzumab)
- Novel Targeted Therapy for Advanced Gastric Cancer
- S1613: Randomized Phase II Study of Trastuzumab and Pertuzumab
- Oncology Therapy for the Generalist
- Perjeta (Pertuzumab) Label
- Fam-Trastuzumab Deruxtecan-Nxki (Enhertu®)
- Oncology Medication Clinical Coverage – Commercial Medical Benefit Drug Policy
- Medication Comments Perjeta (Pertuzumab) N/A OVERRIDE(S
- List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
- T-DM1) with Neratinib in Women with Metastatic HER2- Positive Breast Cancer Jame Abraham,1 Shannon L
- Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (Phesgo™)
- June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
- The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
- Transforming Into Oncology- Sunao Manabe President and COO June 2, 2019 ASCO Investor Relations Presentation, Chicago, IL Forward-Looking Statements
- KADCYLA (Ado-Trastuzumab Emtansine) and Not Trastuzumab
- Immuno-Oncology Management Best Practices 2.0
- Pipeline Report Report
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- Pertuzumab (Perjeta™) National Drug Monograph December 2014 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives
- Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
- Orphan Drug Designations and Approvals List As of 12‐01‐2014
- Biological Product Deviation Reporting and HCT/P Deviation Reporting – Non-Blood Product Codes
- (INN) for Biological and Biotechnological Substances
- Global Oncology
- Precision Cancer Therapy
- BDTX-189 Phase 1 Clinical Data Presentation
- Monoclonal Antibodies in Cancer Therapy
- Redalyc.Pertuzumab and Trastuzumab: the Rationale Way to Synergy
- Assessment of the Evolution of Cancer Treatment Therapies
- Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III
- Clinical Development Strategies and Regulatory Outcomes of FDA Approved Biological License Applications – Therapeutic Domain Considerations
- Publication Agenda CHMP 07-10 December 2020
- BRAVPTRAD Protocol.Pdf
- Emetogenic Potential of Antineoplastic Agents
- Pertuzumab Products MB9438 PERJETA (Pertuzumab) PHESGO (Pertuzumab-Trastuzumab-Hyaluronidase-Zzxf)
- Perjeta (Pertuzumab)
- Breast Cancer